Table 3.
Plasma GFAP, cognitive and motor data in PD patients over different timepoints
| Group | Values | Time | Trend P value | ||
|---|---|---|---|---|---|
| Baseline | 1 year | 2 years | |||
| Total PD | GFAP | 69.79 ± 36.18 | 72.28 ± 38.59 | 74.53 ± 40.38 | 0.560 |
| MoCA | 26.00 (4) | 26.00 (4) | 25.00 (5) | 0.058 | |
| UPDRS-III | 22.96 ± 8.75 | 26.87 ± 9.07 | 30.55 ± 9.73 | 0.000 | |
| TD | GFAP | 68.14 (45.92) | 70.54 ± 30.91 | 68.57 ± 27.69 | 0.969 |
| MoCA | 27.00 (4) | 26.00 (4) | 26.00 (4) | 0.812 | |
| UPDRS-III | 22.34 ± 8.71 | 23.38 ± 7.96 | 28.34 ± 8.54 | 0.001 | |
| Ind | GFAP | 66.68 ± 32.75 | 60.05 (35.76) | 49.79 ± 16.99 | 0.047 |
| MoCA | 27.00 (5) | 27.00 (4) | 26.00 (5) | 0.244 | |
| UPDRS-III | 20.92 ± 8.04 | 25.37 ± 7.61 | 26.32 ± 7.88 | 0.011 | |
| PIGD | GFAP | 69.83 ± 38.30 | 72.23 ± 37.92 | 86.01 ± 47.10 | 0.038 |
| MoCA | 26.00 (3) | 25.00 (5) | 25.00 (5) | 0.181 | |
| UPDRS-III | 24.35 ± 8.95 | 29.45 ± 9.38 | 32.83 ± 10.15 | 0.000 | |
Data are expressed as mean ± SD or median (interquartile range). T-test and Wilcoxon test were used for two-group comparison.
PD Parkinson’ s disease, GFAP Glial fibrillary acidic protein, TD tremor dominant, PIGD postural instability, and gait disturbance, UPDRS unified Parkinson’s disease rating scale, MoCA Montreal Cognitive Assessment.